EUCTR2010-022843-39-DEActive, not recruitingNot Applicable
Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment - Oral alitretinoin in PPP
GlaxoSmithKline R&D Ltd0 sites30 target enrollmentStarted: November 11, 2010Last updated:
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea and a follicle-stimulating hormone concentration of ?40 international units (IU)/L.
- •Child-bearing potential with negative pregnancy test as determined by a human
- •chorionic gonadotropin (hCG) test at screening or prior to dosing and either 1) agrees to use a medically acceptable contraception method for an appropriate
- •period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point and continue contraception until the end of the study, or 2) has only same-sex partners, when this is her preferred and usual lifestyle.
- •2. Capable of understanding and willing to provide signed and dated written voluntary
- •informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed.
- •3. Male or female aged at least 18 years at time of consent and at time of first dose.
- •4. Have PPP for at least 6 months, with or without psoriasis lesions on other areas of
- •5. A PPPASI score of at least 8 with involvement of at least 10% of the palms and/or the soles.
- •6. Refractory to standard topical corticosteroid therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
- •1. Unable to comply with the requirement of the study.
- •2. Female subjects who are pregnant or who plan to become pregnant or who are breast feeding.
- •3. Subjects whose disease is adequately controlled by standard non-medicated therapy (skin moisturizing and protection).
- •4. Known hypersensitivity to other retinoids or vitamin A derivatives, or to any study medication component, especially soybean oil and partly hydrogenated soybean oil.
- •5. Treated with any of the following treatments 4 weeks before the start of study treatment:
- •systemic drugs: corticosteroids, immunosuppressants, methotrexate
- •phototherapy: ultraviolet B light therapy [UVB], psoralen with ultraviolet A
- •combination therapy [PUVA], Grenz rays, X-rays
- •6. Treated with biologic treatments within 6 weeks prior to start of study treatment.
- •7. Abnormal hematology.
- •8. Treated with any systemic or topical retinoids within 3 months or 1 month,
- •respectively, before start of study treatment.
- •9. Treated with high-potency topical corticosteroids within 2 weeks before the start of study treatment.
- •10. Severe generalized pustular psoriasis.
- •11. A skin condition of palms and/or soles that interferes with the diagnosis of PPP by
- •the investigator.
- •12. Any condition that, in the judgment of the investigator, would put the subject at
- •unacceptable risk for participation in the study.
- •13. Hepatic insufficiency, severe renal failure, uncontrolled hypercholesterolemia as characterized by:
- •AST/ ALT > 2.5 x upper limit of normal (ULN)
- •Creatinine clearance <60 mL/min (calculated, Cockcroft-Gault)
- •Fasting triglyceridemia > 1.5 x ULN
- •Fasting cholesterol > 1.5 x ULN
- •Fasting low-density lipoprotein (LDL) cholesterol > 1.5x ULN
- •14. Subjects with hypothyroidism as indicated by TSH above ULN and T4 test below LLN or hypervitaminosis A.
- •15. Subjects with unstable cardiac disease or poorly controlled cardiovascular risk
- •factors, for example:
- •Acute coronary syndrome or coronary revascularization (PCI, CABG) within 3
- •months before start of study treatment
- •Poorly controlled diabetes mellitus (HbA1c > 8.5%)
- •16. Systolic blood pressure =160 mm Hg and/or diastolic blood pressure =100 mm Hg at
- •the screening examination.
- •17. Subjects receiving drugs with a potential for drug-drug interaction, such as systemic tetracyclines, ketoconazole, or St. John’s Wort within 1 Week, or receiving systemic itraconazole within 2 Weeks, before start of study treatment.
- •18. Subjects included in the study of an investigational drug within 2 months before start of study treatment (3 months for biologics).
- •19. Subjects with a score of 20 or more on CES-D, or with active major psychiatric
- •disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar
- •Disorder [I or II], or schizophrenia).
- •20. Subjects who score a 4 or 5 during the previous 30 days on the CSSRS at Screening or Baseline.
- •21. Subjects who have made a suicide attempt within the 6 months preceding the
- •Screening or Baseline visits.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Efficacy of alitretinoin treatment in patients with pustular form of PsoriasisPalmo-Plantar PustulosisMedDRA version: 14.1Level: LLTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 100000004858EUCTR2010-022843-39-NLGlaxoSmithKline R&D Ltd30
Completed
Phase 2
Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatmenthand and foot pustulosisPalmo-plantar pustulosis10014982NL-OMON36734Basilea Pharmaceutica10
Active, not recruiting
Phase 1
Efficacy of altiretinoin treatment in patients with pustular form of PsoriasisPalmo-Plantar PustulosisMedDRA version: 20.0 Level: LLT Classification code 10050185 Term: Palmoplantar pustulosis System Organ Class: 100000004858EUCTR2010-022843-39-GBGlaxoSmithKline R&D Ltd33
Active, not recruiting
Not Applicable
Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand DermatitisSevere Chronic Hand Dermatitis (CHaD) Refractory to Topical TherapyEUCTR2005-004776-20-DEBasilea Pharmaceutica Ltd250
Active, not recruiting
Not Applicable
Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous LupusErythematosus: A Multicentre, Open-Label, Prospective Pilot Study?dult subjects of any ethnicity and either gender with Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions and without major organ involvement to investigate the efficacy of alitretinoin (30 mg per day) in the treatment of Cutaneous Lupus Erythematosus lesions.MedDRA version: 16.0Level: PTClassification code 10056509Term: Cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-024131-16-DEniversitätsklinikum Münster33